David A.Gay Ph.D.

With more than 25 years of experience in the life sciences arena, David Gay focuses his practice on pharmaceutical and biotechnology intellectual property law. He frequently counsels clients facing sophisticated issues arising from the merger of different and complex technologies.

David advises established and emerging biotechnology and pharmaceutical companies on the strategic design, acquisition, and management of intellectual property rights, with particular attention on the integration of business objectives and competitive technologies. His experience includes evaluating patent portfolios and conducting due diligence investigations for venture capital, private, and public financing as well as for mergers and acquisitions in the pharmaceutical and biotechnology areas. A substantial portion of David's practice is devoted to patent portfolio management, U.S. and foreign patent prosecution, opposition proceedings, freedom-to-operate investigations, validity and infringement analyses, and technology licensing. In the area of strategic planning, he advises corporations on the management of portfolios in areas including metabolic engineering, protein and small molecule therapeutics, humanized and fully human antibodies, immunomodulatory agents, cell therapy, including stem and iPSC therapy, gene therapy, pharmaceutical formulations, genomics, proteomics, bioinformatics, nanotechnology, biosensors and diagnostics, as well as in diverse areas of biochemistry, genetics, and molecular biology.

David co-chaired the Special Committee on Biosciences and Chemical Practice for the ABA Section on Intellectual Property Law for two years. Previously, he served as co-chair of the IP section's Licensing Committee and as chair of the Patent Licensing Subcommittee.